ORCID as entered in ROS

Select Publications
, 2009, Hepatitis C: An Expanding Perspective, Dore GJ; Dore G; Lloyd AROLA, (eds.), IP Communications, East Hawthorn
2022, 'Chronic fatigue and postinfective fatigue syndromes', in Clinical Virology Third Edition, pp. 371 - 383, http://dx.doi.org/10.1128/9781555815981.ch17
,2021, 'Drought and Q fever: The association between trends in the incidence of infection and rainfall in rural Australia', in The Encyclopedia of Bacteriology Research Developments, pp. 1975 - 1988
,2018, 'Immunopathogenesis of HIV Coinfections', in Encyclopedia of AIDS, Springer New York, pp. 1083 - 1096, http://dx.doi.org/10.1007/978-1-4939-7101-5_179
,2017, 'Drought and q fever: The association between trends in the incidence of infection and rainfall in rural australia', in Principles and Practice of Q Fever the One Health Paradigm, pp. 301 - 315
,2017, 'Chronic Fatigue and Postinfective Fatigue Syndromes', in Clinical Virology, Fourth Edition, American Society for Microbiology, pp. 373 - 384, http://dx.doi.org/10.1128/9781555819439.ch18
,2016, 'Chronic fatigue and postinfective fatigue syndromes', in Clinical Virology, pp. 371 - 384, http://dx.doi.org/10.1128/9781555819439.ch18
,2014, 'Immunopathogenesis of HIV Coinfections', in Encyclopedia of AIDS, Springer New York, pp. 1 - 15, http://dx.doi.org/10.1007/978-1-4614-9610-6_179-1
,2009, 'Fatigue states following infection', in Yung A; McDonald M; Spelman D; Street A; Johnson P; Sorrell T; McCormack J (ed.), Infectious Diseases A clinical approach, IP Communications, East Hawthorn, Victoria, Australia
,2009, 'Future challenges for hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 433 - 452, http://www.ipcommunications.com.au/
,2005, 'Fatigue states following infection', in Yung A; McDonald M; Spelman D; Street A; Johnson P; Sorrell T; McCormack J (ed.), Infectious Diseases A clinical approach, IP Communications, East Hawthorn, Victoria, Australia, pp. 195 - 204
,1999, 'Chronic fatigue syndrome: current concepts of pathogenesis and treatment', in Current Clinical Topics in Infectious Diseases, Blackwell Science Asia, Carlton, Victoria, pp. 138 - 159
,1999, 'Chronic fatigue syndrome: current concepts of pathogenesis and treatment.', in Current Clinical Topics in Infectious Diseases, Blackwell Science Asia, Carlton, Victoria, pp. 135 - 159
,1997, 'Chronic fatigue syndrome', in Clinical Virology, Churchill Livingstone, New York, pp. 343 - 355
,1997, 'Chronic fatigue syndrome', in Clinical Virology, Churchill Livingstone, New York, pp. 343 - 355
,1997, 'Treatment of chronic fatigue syndrome', in Intravenous Immunoglobulins in Clinical Practice, Marcel Dekker, New York, pp. 267 - 274
,1991, 'The response of patients with chronic fatigue syndrome to intravenously administered gammaglobulin', in Immunotherapy with Intravenous Immunoglobulins, Elsevier, pp. 377 - 386, http://dx.doi.org/10.1016/b978-0-12-370725-3.50039-7
,2025, 'Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison: a qualitative study', International Journal of Drug Policy, 142, pp. 104831 - 104831, http://dx.doi.org/10.1016/j.drugpo.2025.104831
,2025, 'Anti-HCV antibodies: A battle for breadth and potency', Antiviral Research, 238, http://dx.doi.org/10.1016/j.antiviral.2025.106165
,2025, 'Multidimensional outcomes associated with chronic fatigue over 12 months in youth with emerging mood disorders', Journal of Psychosomatic Research, 193, http://dx.doi.org/10.1016/j.jpsychores.2025.112141
,2025, 'Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics', Virus Research, 355, http://dx.doi.org/10.1016/j.virusres.2025.199566
,2025, 'Diagnosing and Preventing Q Fever in Regional New South Wales, Australia—A Qualitative Exploration of Perspectives of General Practitioners', Australian Journal of Rural Health, 33, http://dx.doi.org/10.1111/ajr.70030
,2025, 'Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach', CNS Drugs, 39, pp. 305 - 320, http://dx.doi.org/10.1007/s40263-024-01153-5
,2025, 'Early circulating biomarkers to predict plasma leakage in dengue fever', Journal of Infection, 90, http://dx.doi.org/10.1016/j.jinf.2024.106401
,2025, 'Apathy is distinct from depression or fatigue and is associated with poor physical health in an older community cohort', International Psychogeriatrics, http://dx.doi.org/10.1016/j.inpsyc.2025.100089
,2024, 'Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease', Journal of Experimental Medicine, 221, http://dx.doi.org/10.1084/jem.20240942
,2024, 'Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants', Ebiomedicine, 110, http://dx.doi.org/10.1016/j.ebiom.2024.105461
,2024, 'Co-designing the INHSU Prisons Hepatitis C Advocacy Toolkit using the Advocacy Strategy Framework', International Journal of Drug Policy, 134, http://dx.doi.org/10.1016/j.drugpo.2024.104628
,2024, 'Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study', Lancet Regional Health Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101240
,2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007, http://dx.doi.org/10.1111/liv.16074
,2024, 'Homoeologous crossovers are distally biased and underlie genomic instability in first-generation neo-allopolyploid Arabidopsis suecica', New Phytologist, 244, pp. 1315 - 1327, http://dx.doi.org/10.1111/nph.20095
,2024, 'Next-Generation Sequencing Methods for Near-Real-Time Molecular Epidemiology of HIV and HCV', Reviews in Medical Virology, 34, http://dx.doi.org/10.1002/rmv.70001
,2024, 'B-cell characteristics define HCV reinfection outcome', Journal of Hepatology, 81, pp. 415 - 428, http://dx.doi.org/10.1016/j.jhep.2024.04.004
,2024, 'Using nominal group technique with people who are incarcerated in Canadian federal prisons to identify barriers and solutions to improving Prison Needle Exchange Program uptake', International Journal of Drug Policy, 131, http://dx.doi.org/10.1016/j.drugpo.2024.104549
,2024, 'Acute Q fever in patients with an influenza-like illness in regional New South Wales, Australia', Plos Neglected Tropical Diseases, 18, http://dx.doi.org/10.1371/journal.pntd.0012385
,2024, 'Discovery of a monoclonal, high-affinity CD8+ T-cell clone following natural hepatitis C virus infection', Immunology and Cell Biology, 102, pp. 630 - 641, http://dx.doi.org/10.1111/imcb.12791
,2024, 'Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons', International Journal of Drug Policy, 130, http://dx.doi.org/10.1016/j.drugpo.2024.104516
,2024, 'Using nominal group technique to identify perceived barriers and facilitators to improving uptake of the Prison Needle Exchange Program in Canadian federal prisons by correctional officers and healthcare workers', International Journal of Drug Policy, 130, http://dx.doi.org/10.1016/j.drugpo.2024.104540
,2024, 'Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia', Lancet Regional Health Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101139
,2024, 'Development of an evidence-based hepatitis C education program to enhance public health literacy in the Australian prison sector: The Hepatitis in Prisons Education program (HepPEd)', International Journal of Drug Policy, 129, http://dx.doi.org/10.1016/j.drugpo.2024.104461
,2024, 'Controlling COVID-19 outbreaks in the correctional setting: A mathematical modelling study', Plos One, 19, http://dx.doi.org/10.1371/journal.pone.0303062
,2024, 'Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit', International Journal of Drug Policy, 126, http://dx.doi.org/10.1016/j.drugpo.2024.104386
,2024, 'People in community corrections are a population with unmet need for viral hepatitis care', Eclinicalmedicine, 70, http://dx.doi.org/10.1016/j.eclinm.2024.102548
,2024, 'Reply to: “ ‘One-stop-shop’ point-of-care hepatitis C RNA testing intervention in the prison – some issues”', Journal of Hepatology, 80, pp. e107 - e108, http://dx.doi.org/10.1016/j.jhep.2023.10.020
,2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, pp. ofad637, http://dx.doi.org/10.1093/ofid/ofad637
,2024, 'Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial', Brain Behavior and Immunity, 115, pp. 191 - 200, http://dx.doi.org/10.1016/j.bbi.2023.10.012
,2024, 'Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2024.104401
,2024, 'Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes', Journal of Medical Virology, 96, http://dx.doi.org/10.1002/jmv.29381
,2024, 'Corrigendum: Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries (Frontiers in Public Health, (2024), 12, (1279572), 10.3389/fpubh.2024.1279572)', Frontiers in Public Health, 12, http://dx.doi.org/10.3389/fpubh.2024.1478843
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,